 OSAKA, Japan--BUSINESS WIRE--Takeda Pharmaceutical Company Limited TSE:4502NYSE:TAK Takeda today announced results from two final analyses from the Phase 3 HELP Hereditary Angioedema Long-term Prophylaxis StudyTM Open-label Extension OLE, which evaluated the long-term safety primary endpoint and efficacy of TAKHZYRO lanadelumab 300 mg every two weeks for up to 2.5 years. In the first analysis, the mean min, max reduction in the attack rate compared to baseline observed in the 